Skyhawk Therapeutics, Inc. today announced that Fidelity Management & Research Company LLC has led a $133 million oversubscribed investment round in Skyhawk, along with other major investors. This brings total equity funding plus partnership capital in the Company to over $600 million thus far, with potential future milestones of over $20 billion plus ongoing royalties.

Skyhawk Therapeutics is committed to discovering, developing and commercializing therapies that use its novel SkySTARTM (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) platform to build small molecule drugs that bring breakthrough treatments to patients.
For more information visit: www.skyhawktx.com, https://twitter.com/Skyhawk_Tx, https://www.linkedin.com/company/skyhawk-therapeutics/
SKYHAWK MEDIA CONTACT:Anne Deconinck[email protected]
SOURCE Skyhawk Therapeutics

Skyhawk Therapeutics Completes New Investment Round

Description

Company Information

Skyhawk Therapeutics Completes New Investment Round

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Company Information